COTA (USA)
Database Contact Data
Email: info@cotahealthcare.com
Alternate Contact
If you cannot reach the database manager, please try completing the contact form at:
https://cotahealthcare.com/contact/
References of Studies Using/Describing Database
1. Hoff FW, Patel PA, Belli AJ, Hansen E, Foss H, Schulte M, Wang CK, Madanat YF. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023 Apr 13:1-6.
2. Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Stenzinger A, Thomas M. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. J Thorac Oncol. 2023 Feb 3:S1556-0864(23)00095-3.
3. Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022 Jun;168:74-82.
4. Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):373-381.
5. Kushi LH, Lasiter L, Belli AJ, et al. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data. Journal of Clinical Oncology 2020;38:e19311-e.
6. Rivera DRR, Lasiter L, Christian J, et al. Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration. Journal of Clinical Oncology 2020;38:e19270-e.
7. Mathura S, Fung VK, Dilwali K, Lakshmanan AS. Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data. Journal of Clinical Oncology 2020;38:e19251-e.
8. Mathura S, Lane D, Hansen E, et al. Disparities in clinical characteristics and treatment of multiple myeloma in African American patients. Journal of Clinical Oncology 2020;38:e19008-e.
9. Lane D, Norden AD, Belli AJ, Wang C-K. Assessing real-world clinical response in patients with multiple myeloma (MM): A survey of the literature. Journal of Clinical Oncology 2020;38:e19260-e.
10. Gutierrez ME, Price KS, Lanman RB, et al. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precision Oncology 2019:1-9.
9/17/20: Special Offer for ISPE Members
We are offering a 10% discount for first time subscribers of our resource www.bridgetodata.org.
New users must sign up by October 15, 2020. Contact us for more information
9/16/20: Don't forget to check out DGI's poster at ICPE
There is a growing interest among epidemiologists to investigate genetic risk factors for disease, alongside other risk factors. We present a case study that demonstrates how B.R.I.D.G.E. TO DATA® (www.bridgetodata.org) supports gene-disease association studies by allowing searching for genetic databases, reviewing data elements, and comparing cohorts for pooling.
9/15/20: BTD at ICPE All Access 2020
We may not have a booth at this year’s virtual meeting for ICPE, but you can always visit us at our website to request a demo, view a sample set, or communicate with our DGI Team.
9/4/20: 95th profile from USA: Flatiron RWE Data for Oncology
The Flatiron Health database is a longitudinal and nationwide database comprised of de-identified patient-level structured and unstructured data from an EHR data source, curated via technology-enabled abstraction. It includes de-identified data from >280 cancer clinics representing more than 2.5 million U.S. cancer patients.
Keep a look out for our latest poster, Data Sources for Studying Genetic Factors of Chronic Obstructive Pulmonary Disease (COPD), to be presented at ICPE 2020 (Sep. 16-17, 2020).
Flatiron RWE Data for Oncology (USA)
Database Contact Data
Flatiron Heath
233 Spring Street
New York, NY 10013
USA
(Submit requests online at https://flatiron.com/contact/)
Alternate Contact
N/A
References of Studies Using/Describing Database
1. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. Int J Cancer. 2024 Feb 15;154(4):701-711.
2. Nicholson G, Carlson KB, Hernandez RK, Schenfeld J, Cadieux B, Henry D, De Sousa Barbosa VJ, Saad H. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018. Am J Clin Oncol. 2024 Jan 11. doi: 10.1097/COC.0000000000001075. Epub ahead of print.
3. Castellanos EH, Wittmershaus BK, Chandwani S. Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions. JCO Clin Cancer Inform. 2024 Jan;8:e2300046.
4. Hantel A, Cernik C, Uno H, Walsh TP, Calip GS, DeAngelo DJ, Lathan CS, Abel GA. Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood Cancer J. 2023 Dec 21;13(1):192.
5. Passamonti F, Lou Y, Chevli M, Abraham P. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. Future Oncol. 2023 Nov 22. doi: 10.2217/fon-2022-1256.
6. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice. Cancers (Basel). 2023 Nov 2;15(21):5268.
7. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist. 2023 Oct 3;28(10):866-874.
8. Eyre TA, Hess LM, Sugihara T, He D, Khanal M, Pagel JM, Walgren RA, B Abada P, Konig H, Roeker LE, Mato A. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leuk Lymphoma. 2023 May;64(5):1005-1016.
9. Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023 Apr;102(4):749-754.
10. Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar S, Lee JK, Fisher V, Oxnard GR, Tukachinsky H. Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma. Clin Cancer Res. 2023 Mar 14;29(6):1056-1067.